Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oral film-based therapeutics - IntelGenx

Next Previous
Search
Drug Profile

Research programme: oral film-based therapeutics - IntelGenx

Alternative Names: INT 0015/2008; INT 0037; INT 0037/2013; INT 0040/2013; INT 0041/2015; INT 0042/2015; INT 0045/2018

Latest Information Update: 01 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IntelGenx Corp.
  • Class Carbolines
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Mouth disorders

Highest Development Phases

  • No development reported Alzheimer's disease; Unspecified
  • Discontinued Erectile dysfunction; Panic disorder

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 28 Apr 2021 No recent reports of development identified for research development in Unspecified in Canada (PO, Film)
  • 25 Mar 2021 IntelGenx Corp receives patent allowance for topical oral films in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top